Prevention of Prostate Cancer: Outcomes of Clinical Trials and Future Opportunities | Zendy

Ian M. Thompson | Zendy; Alan R. Kristal | Zendy; Elizabeth A. Platz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prevention of Prostate Cancer: Outcomes of Clinical Trials and Future Opportunities

Author(s) -

Ian M. Thompson,

Alan R. Kristal,

Elizabeth A. Platz

Publication year - 2014

Publication title -

american society of clinical oncology educational book

Language(s) - English

Resource type - Journals

eISSN - 1548-8756

pISSN - 1548-8748

DOI - 10.14694/edbook_am.2014.34.e76

Subject(s) - finasteride , prostate cancer , medicine , oncology , disease , clinical trial , cancer , cancer prevention , prostate , vitamin d and neurology , randomized controlled trial , gynecology

Prostate cancer is an excellent target for prevention, to reduce both mortality and the burden of overdetection of potential inconsequential disease whose diagnosis increases cost, morbidity, and anxiety. The Prostate Cancer Prevention Trial has demonstrated that finasteride significantly reduces the risk of prostate cancer but only low-grade disease; overall survival is unaffected. In the Selenium and Vitamin E Cancer Prevention Trial (SELECT) clinical trial, selenium had no effect on prostate cancer risk, but alpha tocopherol significantly increased the risk by 17%. The most promising future approaches to prostate cancer prevention will likely focus on nutrition, especially weight control, and through modulation of inflammation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research